<DOC>
	<DOC>NCT02093819</DOC>
	<brief_summary>To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics (PK) of single rising doses of BI 416970. A further objective is to assess the influence of CYP2C9 phenotype on the PK of BI 416970.</brief_summary>
	<brief_title>To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: Healthy males according to the investigator's assessment, based on a complete medical history including a physical examination, vital signs (Blood Pressure, Pulse Rate), 12lead electrocardiogram, and clinical laboratory Age 18 to 50 years (incl.) Body Mass Index 18.5 to 29.9 kg/m2 (incl.) Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation Known genotype of CYP2C9 isoenzyme Exclusion criteria: Any finding in the medical examination (including Blood Pressure, Pulse Rate or Electrocardiogram) is deviating from normal and judged as clinically relevant by the investigator Repeated measurement of systolic blood pressure outside of ranges 90140 mmHg, diastolic blood pressure outside of ranges 5090 mmHg, or pulse rate outside the range of 50 to 90 bpm Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease judged as clinically relevant by the investigator Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication Diseases of the central nervous system (such as epilepsy), other peripheral neurological disorders or psychiatric disorders</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>